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Abstract
Objective
To develop and validate a patient report outcome measure (PROM) for clinical practice that
can monitor health status of patients with a range of musculoskeletal (MSK) disorders.
Methods
Constructs for inclusion in the MSK-PROMwere identified from a consensus process in-
volving patients with musculoskeletal conditions, clinicians, purchasers of healthcare ser-
vices, and primary care researchers. Psychometric properties of the brief tool, including
face and construct validity, repeatability and responsiveness were assessed in a sample of
patients with musculoskeletal pain consulting physiotherapy services in the United Kingdom
(n=425).
Results
The consensus process identified 10 prioritised domains for monitoring musculoskeletal
health status: pain intensity, quality of life, physical capacity, interference with social/leisure
activities, emotional well-being, severity of most difficult thing, activities and roles, under-
standing independence, and overall impact. As the EuroQol (EQ-5D-5L) is a widely adopted
PROMs tool and covers the first four domains listed, to reduce patient burden to a minimum
the MSK-PROM was designed to capture the remaining six prioritised domains which are
not measured by the EQ-5D-5L. The tool demonstrated excellent reliability, construct validi-
ty, responsiveness and acceptability to patients and clinicians for use in clinical practice.
Conclusion
We have validated a brief patient reported outcome measure (MSK-PROM) for use in clini-
cal practice to measure musculoskeletal health status and monitor outcomes over time
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using domains that are meaningful to patients and sensitive to change. Further work will es-
tablish whether the MSK-PROM is useful in other musculoskeletal healthcare settings.
Introduction
Patient Reported Outcome Measures (PROMs) are defined as “. . . any report of the status of a
patient’s health condition that comes directly from the patient, without interpretation of the
patient’s response by a clinician or anyone else”[1]. Appropriate PROM tools for longer-term,
fluctuating musculoskeletal disorders, are particularly important as their clinical management
is primarily focused on addressing symptoms rather than laboratory results or biomarkers. The
need for PROMs that are primarily designed for clinical practice rather than research is also in-
creasing in order to place patients’ needs, interests and feedback at the centre of care[2–4].
PROMs are recognised for their role as catalysts for organisational change both through their
use at an aggregate level (e.g. audits)[3,4], and individual level (e.g. helping patients to monitor
their own health)[5]. Momentum among policy makers is growing for the collection of
PROMs data in order that clinical services can provide standardised reports of their clinical
outcomes[6]. An example which reflects this trend within musculoskeletal healthcare is the
UK’s National Health Service Programme for PROMs (http://www.ic.nhs.uk/proms) which
aims to raise healthcare standards by reporting provider performance for high-cost surgical
procedures including hip and knee joint replacement.
Outcome measures can be categorised into those which are ‘condition specific’ and those
which are ‘generic’ and are applicable across different health conditions. The EuroQol (EQ-
5D)[7] is a high profile PROM used to evidence outcomes of care as it is ‘generic’ and enables
comparisons of health status improvements across different patient populations[6]. Its scores
can also be converted into ‘utility estimates’ that are used in health economic evaluations[2,7].
The EQ-5D has five items; mobility, self-care, usual activities, pain and emotional health, each
with three response options and has recently been superseded by the EQ-5D-5L[8] which offers
five response levels to reduce ceiling effects and improve discriminatory power[9]. The EQ-
5D-5L has therefore been recommend for clinical use within musculoskeletal (MSK) popula-
tions and has been adopted by the UK National PROMs Programme and professional organi-
sations including the Chartered Society of Physiotherapy (www.csp.org.uk/proms). In addition
to generic PROMs clinical services may also collect condition specific outcomes with greater
relevance and responsiveness to their particular patient population, such as the Roland Morris
Disability Questionnaire for low back pain[10], or the Oxford Knee Score for knee osteoarthri-
tis[11]. However, capturing condition specific data for multiple musculoskeletal disorders can
be difficult in routine practice and clinicians have therefore called for more feasible, simple yet
fit for purpose PROM tools which can assess overall health status of patients with MSK pain
different body regions (e.g. knee, shoulder and neck). At present numerous lengthy research in-
struments are available for musculoskeletal disorders that are specific to regions of the body
and that measure individual constructs (e.g. the Roland Morris Disability Questionnaire has 24
items to capture physical function in people with low back pain). However, clinicians and pa-
tients do not find such research measures practical for routine clinical care and self-monitoring
purposes, particularly since they are perceived as too long for use in clinical practice and be-
cause many patients have more than one musculoskeletal pain problem [12,13]. Instead new
tools are needed that can be applied across a range of common musculoskeletal disorders,
which cover a range of different constructs, and are designed for use in clinical practice and
Development and Validation of the MSK-PROM
PLOSONE | DOI:10.1371/journal.pone.0124557 April 30, 2015 2 / 14
found on the Centre’s website http://www.keele.ac.uk/
pchs/publications/datasharingresources/ or by e-
mailing the Centre’s Data Manager ( primarycare.
datasharing@keele.ac.uk).
Funding: This abstract presents independent
research funded by the National Institute for Health
Research (NIHR) under its Programme Grants for
Applied Research Programme (Grant Reference
Number PB-PG-0909-20283) (http://www.nihr.ac.uk/
funding/research-for-patient-benefit.htm). Nadine
Foster is supported through a NIHR Research
Professorship (NIHR-RP-011-015). The funders had
no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
therefore and brief, simple to use and interpret. Such a tool does not seek to replace research
measures, but to enable routine objective clinical assessment of key constructs that are perti-
nent to a particular patient population, ie. those with common musculoskeletal disorders. Im-
portant requirements for such a musculoskeletal PROM would be to; include priority health
outcomes for musculoskeletal patients, be easily interpretable and feasible for use in busy clini-
cal practice, provide excellent reliability and superior responsiveness to existing measures used
for this purpose, such as the EQ-5D-5L.
In this study we therefore aimed to develop and validate a brief musculoskeletal (MSK)
pain-specific PROM (MSK-PROM) suitable for clinical practice. The specific objectives were:
1) to prioritise the primary outcomes of treatment for musculoskeletal disorders with stake-
holders, including patient and clinician representatives, 2) to develop an MSK-PROM to mon-
itor these outcomes with strong face and content validity, 3) to investigate test-retest
reliability, convergent construct validity and responsiveness of the candidate MSK-PROM
compared to EQ-5D-5L, and 4) to examine its feasibility and acceptability for use in routine
clinical consultations.
Methods
Objective 1: Prioritising outcome domains for musculoskeletal disorders
Consensus workshops. Two iterative consensus workshops were held with regional stake-
holders (including musculoskeletal; patients, clinicians, researchers, service managers and pur-
chasers) to agree and prioritise treatment targets/outcomes for MSK-PROM inclusion. All
participants provided informed written consent and were remunerated according to INVOLVE
recommendations[14]. A nominal group technique[15] consensus process was used involving:
a study presentation, small group discussions (including a dedicated patient group) to identify
potential health domains for inclusion, a full group discussion, a blind vote to retain domains
with broad consensus (defined as>50% of participants), and finally individual participant
ranking of domains. Patient perspectives were specifically prioritised throughout this process.
Participants attended a second workshop two weeks later to further discuss and revise the list
of ranked domains before re-ranking them again.
A national stakeholder consultation. An on-line survey then established if the health do-
mains identified by the regional group of stakeholders were considered a priority nationally.
Participants were recruited through advertisments in national stakeholder forums and chariti-
ble organisation websites including Back Care, the Arthritis Rheumatism Musculoskeletal Al-
liance, Arthritis Care and the Chartered Society of Physiotherapy’s interactive online forum—
iCSP and the Physiotherapy Consultant’s Forum. The survey sought participant consent,
identified if the particpant was a health professional or patient, and then presented a list of the
top ten ranked health domains for musculoskeletal disorders alongside a separate list of iden-
tified domains that were not ranked within the top ten. Participants were asked four ques-
tions: i) if they agreed with domains on the top ten list, ii) if they agreed with the ranking of
constructs, iii) whether other important health domains were missing, and iv) if they had any
additional comments.
The results were collated and examined by the research team including two patient
representatives.
Objective 2: Developing the MSK-PROM
Having prioritised key musculoskeletal outcomes, single items for each domain were formulat-
ed during two interactive face validity workshops with five members of the Research Institute’s
established musculoskeletal Research User Group and two experienced musculoskeletal clinical
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researchers. This process generated an item for each domain that was clear to users and had ap-
propriate and optimal content validity. Domains already captured by the EQ-5D-5L were ex-
amined to avoid unneccessary duplication with the MSK-PROM. The readability and
comprehensibility of tool items, instructions and response options were examined. The culmi-
nation of this process was a draft MSK-PROM ready for psychometric testing.
Objective 3: Measurement properties of the MSK-PROM
Design and setting. A prospective cohort study was conducted among out-patient muscu-
loskeletal physiotherapy clinics in five UKWest Midlands towns (Congleton, Cannock,
Shrewsbury, Oswestry, Cheadle). These clinics provide individual, face-to-face treatments
within the UK National Health Service (NHS) with most patients accessing care following a re-
ferral from their General Practitioner (GP) or hospital specialist. Participants received usual
physiotherapy care according to clinical need.
Patient selection. Consecutive adult (> = 18 years) consulters with a musculoskeletal dis-
order were invited to participate having received a study information pack with their clinic ap-
pointment. No further inclusion/exclusion criteria were used. Consenting participants were
also asked for further consent to receive an invitation to a post-study feedback workshop to dis-
cuss their experiences of using the MSK-PROM.
Population descriptors. Prior to initial clinical assessment within the physiotherapy clin-
ic, participants completed a questionnaire containing baseline population descriptors (see S1
Text—Musculoskeletal Case-Mix Descriptors) including demographic data (age, gender,
work status) and patient/pain characteristics: pain related days off work over past three
months, referral source/clinician, site of main musculoskeletal problem (collapsed into upper
limb, lower limb, spinal, or multi-site pain), pain episode duration, number of pain related vis-
its to their GP in past 3 months, outcome expectations (using a numerical response scale from
0 ‘it will get worse’ to 10 ‘it will be cured’), a single pain catastrophising item from a validated
screening tool for back pain patients (the STarT Back Tool[16]) ‘Do you feel that your problem
is terrible and that it is never going to get any better?’ using a numerical response scale (0
‘completely disagree’ to 10 ‘completely agree’), and self-rated general health using the SF-36
item[17] on a scale of 0 ‘poor health’ to 100 ‘perfect health’).
Outcome measures. Outcome measures were collected before the start of treatment at
each visit and at three-month follow-up using paper questionnaires containing the
MSK-PROM and EQ-5D-5L[8]. The EQ-5D-5L utility score was calculated using the UK
Crosswalk value set[8], and the sum score (range 5–25) simply summed responses for all five
items (from 1 ‘no problems’ to 5 ‘unable/extrem). To ensure simplicity of the MSK-PROM
scoring, which emerged as important during the consensus workshops, scores from all six
items are summed together (responses coded from ‘never’ = 1 to ‘all the time’ = 5) providing
a range from 6–30. The MSK-PROM overall score is not a score of a single construct (reflec-
tive model), but a sum of items from six different domains measuring overall musculoskele-
tal health status (formative model). In line with methodology guidelines for multi-
dimensional instruments, internal consistency of the MSK-PROM overall score was there-
fore not examined.[18] Patient global rating of improvement, a recommended core outcome
in chronic musculoskeletal and osteoarthritis trials[19,20] was captured at all follow-up vis-
its (up to five times) and three-month questionnaire. The item asked “Overall compared to
the start of treatment, my symptoms are: much better, better, same, worse, or much worse”.
Postal data collection at three-month follow-up was used to reduce attrition bias[21], pro-
vide a standardised end-point, and ensure follow-up of those attending for just one physio-
therapy visit.
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Statistical analysis and sample size. MSK-PROM and EQ-5D scores were not calculated
for participants with any missing baseline data. However, for those who responded and com-
pleted their follow-up questionnaires, incidental missing data for individual MSK-PROM items
were imputed using the last observation carried forward method if two or less MSK-PROM
items were missing[22]. This approach has been shown to be valid particularly in situations
where repeated data time-points are available for the same individual [22]. A sensitivity analysis
was conducted to test if the results were similar when using complete cases only. MSK-PROM
response rates and floor/ceiling effects (<10% of lowest (6) or highest (30) scores) were ex-
plored through descriptive analysis.
To examine test re-test reliability among ‘stable’ patients, we used a sample of those who re-
ported they were “the same” on the global improvement item at the second visit (typically after
two weeks). Based on previous cohort data this was estimated to be 30% of patients[16]. Pa-
tients completed the MSK-PROM in the same clinical setting at both their first and their sec-
ond visit in order to examine test re-test reliability. An intraclass correlation coefficient (ICC—
based on a two-way random effect model) tested the overall MSK-PROM score reliability with
the ICC considered acceptable/good when above 0.70, and a weighted Cohen’s Kappa tested
item-by-item agreement[18].
To examine the convergent construct validity of the MSK-PROM and EQ-5D-5L, the Pear-
son correlation between raw sum scores of both instruments at baseline was calculated[18] and
to illustrate the relationship between both scale’s distributional characteristics, a boxplot
was produced.
To examine responsiveness (sensitivity to change) we calculated the Area Under the Receiv-
er Operating Characteristic Curve (AUC) for discriminating any improvement, from no
change or deterioration on the external anchor measured by the global improvement question
at three-month follow-up[18]. The AUC for the MSK-PROM alone was compared to that for
the EQ-5D-5L and in addition to a combined variable which summed both tools together
(score range of 11–55). In sensitivity analyses, the effect size[23] and standardised response
mean[24] were also reported. The effect size is the mean change in tool score divided by the
standard deviation of baseline score, and the standardised response mean is the mean change
in score divided by the standard deviation of mean change (a higher value indicates higher re-
sponsiveness for both). The standard error of measurement was calculated as an indicator of
error variation in this population, using baseline score standard deviation multiplied by the
square root of 1-ICC.
The sample size (n = 425) for the validation cohort was calculated from the minimum num-
ber of patients recommended to investigate MSK-PROM; a) responsiveness[25] at three-
month follow-up (n = 150) with an estimated three-month postal questionnaire response rate
of 50%, and b) reliability among stable patients at the second physiotherapy visit with an esti-
mated 20% loss to follow up of patients between first and second visits and 30% reporting sta-
ble symptoms. Using the Donner & Eliasziw[26] approach for estimating sample size for
reliability testing we calculated that 102 people were needed to detect a minimum acceptable
ICC of 0.70, assuming a true ICC of 0.80, with a power of 80% and 5% significance level.
Objective 4: MSK-PROM’s feasibility and acceptability for clinical
practice
Following completion of the cohort study, a two hour structured feedback workshop was held
at the Research Institute with patient and clinician participants from the cohort to discuss the
acceptability and feasibility of the MSK-PROM in clinical practice and to agree any modifica-
tions required. In addition, participants were asked to discuss potential mis-uses of the
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measure. Two clinicians from each clinic were invited (a total of 10) and a random selection of
participants were invited to ensure that 1 patient agreed to attend from each clinic, using a se-
quence formed by a random number generator to reduce selection bias.
Results
Objective 1: Prioritising outcome domains for musculoskeletal disorders
Consensus workshops. The two workshops were attended by four patients, six clinicians,
six researchers, four clinical managers and one purchaser of care. The list of 10 prioritised do-
mains is provided in Table 1 and, in ranked order, included: pain intensity, severity of the one
thing that is most difficult, understanding about how to deal with symptoms, physical function,
quality of life, work interference, independence, ability to do activities and roles that matter, in-
terference with social/leisure activities, and overall impact. Patients and clinicians did not have
strongly different domain preferences, but largely agreed with each other. For practical reasons
to limit the burden on patients, participants suggested a cap of around 10 domains should be
prioritised for inclusion in the PROM tool. However, due to the rankings domains 11–13 were
also integrated into the final PROM.
National consultation survey. The online survey was completed by 80 respondents (35
[44%] patients and 45 [56%] clinicians) and confirmed the importance and relevance of the do-
mains with over two-thirds agreeing with the ranking (71%). There were 23 (29%) respondents
who disagreed with the ranking and their comments are provided in S2 Text—Survey Feed-
back Comments. In summary, based on survey responses, anxiety and depression were added
to the priority list, but no other suggestions were added for practical reasons to keep the tool
short and because additional domains had lower ranking scores. In addition, some patients
Table 1. Identified health domains for musculoskeletal disorders (in ranked order).
Top 10 health domains in ranked order: [rank score]
1. Pain intensity * [323]
2. Severity of the thing that is most difﬁcult [280]
3. Ability to self-manage (understanding how to deal with the symptoms by yourself) a [273]
4. Physical function * [254]
5. Quality of life * [251]
6. Work interference [234]
7. Independence without help of others [224]
8. Ability to do activities/roles that matter [194]
9. Interference with social/leisure activity *[191]
10. Overall impact (bothersomeness) [167]
Important health domains with consensus but not ranked in the top 10:
11. Anxiety/worry (feelings of worry) * a [166]
12. Mood /depression * a [160]
13. Difﬁculties with sleep [154]
14. Fatigue (lack of energy) [120]
15. Knowledge of condition a [119]
16. Fear of physical activity harm [116)
17. Ability to cope with symptoms [85]
* Domains already included in the EQ-5D-5L
a The online consultation survey highlighted importance of ‘anxiety’ and ‘mood’ domains, and patient’s
‘Knowledge of condition’ was merged with domain 3 ‘ability to self-manage’
doi:10.1371/journal.pone.0124557.t001
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were confused by the term ‘self-manage’ and suggested ‘understanding about how to deal with
symptoms by yourself’ was similar to ‘Knowledge of condition’. Therefore, these two domains
were merged together giving a final list of 11 prioritised outcome domains.
Objective 2: Developing the MSK-PROM
During the face validity workshops with five patient representatives it was agreed that any
prioritised domains that were already included in the EQ-5D—so pain intensity, physical ca-
pacity (using walking and dressing items), quality of life, interference with social and leisure ac-
tivities and anxiety/mood) had appropriate content validity and would therefore not be needed
within the MSK-PROM. This means that the MSK-PROM needs to be used alongside the EQ-
5D-5L to capture all prioritised domains, and only needs to capture the six remaining priori-
tised health domains not covered by the EQ-5D-5L; overall impact using a modified bother-
someness question[27]; work interference using a new item loosely based on the SF-36[17]
work item; and new items for severity of the one thing that’s most difficult, understanding
about how to deal with the condition, independence, and ability to do activities and roles that
matter (See S3 Text—The Keele MSK-PROM). Patient representatives preferred response op-
tions that expressed ‘frequency’ (‘how often’) rather than ‘severity’ (‘how much’) due to the
fluctuating nature of their symptoms, and wanted the results of their previous visit entries to
appear on the same page to assist self-monitoring as recommended for monitoring tools
[28,29]. On average the MSK-PROM took around one minute to complete (similar to the EQ-
5D-5L). The Flesch-Kincaid reading grade level of the MSK-PROM is 4.7 which suggests it is
“very easy to read”. Patient representatives confirmed they were satisfied with the content va-
lidity of the MSK-PROM in capturing the domains identified and that it had appropriate read-
ability and was easy to understand.
Objective 3: Measurement properties of the MSK-PROM
There were 425 musculoskeletal patients who consented to participate in the cohort study from
a potential pool of 1038 new (incident) patients over a three-month recruitment period (41%
participation rate). Patients accessed physiotherapy predominantly following a GP referral
(75%) although 19% were referred from a hospital specialist, 3% from Accident and Emergen-
cy, 1% from self-referral, and 2% were referred from other clinics. Baseline population charac-
teristics, summarised in Table 2, showed a mean age of 53 years (SD 15.2, range 18–94) with
64% female. The most common region of musculoskeletal pain was the low back (23.3%) and
the median pain episode duration was seven months (IQR 3–24). At the second physiotherapy
visit 339 (79.8%) completed the MSK-PROM, and 225 patients (53%) returned a completed,
postal, three-month follow-up questionnaire.
Completion rates. Complete MSK-PROM and EQ-5D-5L baseline data were available for
417/425 patients (98.1%). The best completed MSK-PROM item was ‘overall impact’ with no
missing data and the work item had the most with six missing responses (1.4%) and 158 (37%)
‘not applicable’ responses (due to participants not being in paid work). Due to the high propor-
tion of ‘not applicable’ responses, this item was modified to include ‘daily routine’ to ensure ap-
plicability to all patients. The scoring distribution means and SDs for MSK-PROM, EQ-5D-5L
sum score and utility score, and a combined MSK-PROM and EQ-5D-5L sum score for first
visit data are presented in Fig 1. No weighting was given to any items in order to ensure that
the MSK-PROM is simple to use and interpret in clinical practice.
Test-retest reliability. There were 129/339 patients (38.0%) reporting ‘stable’ health status
between baseline and their second physiotherapy visit (with a 14 day mean time interval) with
41.5% better and 7.4% worse. Within this stable sample the 6-item MSK-PROM sum score
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ICC was 0.98 (95% CI .97–.99) demonstrating ‘excellent’ reliability and comparable to the EQ-
5D-5L sum score ICC of 0.99 (95%CI 0.99, 0.99). The weighted Cohen’s Kappa item-by-item
agreement for the MSK-PROM items ranged from 0.96 (95%CI 0.93, 0.98) for ‘work interfer-
ence’ to 0.82 (95%CI 0.73, 0.90) for ‘severity of the most difficult thing’. The number of
Table 2. Patient characteristics at baseline.
Patient characteristics Total patient number = 425
Age (years) 53.3 (SD 15.2, range 18–94)
Sex, female (n = 418) 271 (63.8%)
Work status (n = 391)
No time off work 146 (4.4%)
Retired 124 (9%)
Time off in past 3 months, now back at work 44 (10.4%)
Not in work due to health problems 35 (8.2%)
Not in work, not due to health problems 23 (5.4%)
Currently on sick leave 19 (4.5%)
Referral source (n = 416)
General practitioner (GP) 312 (73%)
Hospital specialist 78 (18.4%)
Accident and emergency 13 (3.1%)
Other health professional 9 (2.1%)
Self-referral 4 (0.9%)
Site of main musculoskeletal problem (n = 424)
Back 98 (23.1%)
Multi-site pain 83 (19.6%)
Shoulder 59 (13.9%)
Knee 47 (11.1%)
Neck 41 (9.7%)
Ankle/foot 40 (9.4%)
Hip 27 (6.4%)
Other 13 (3.1%)
Wrist 8 (1.9%)
Elbow 5 (1.2%)
Hand 3 (0.7%)
Visited GP for musculoskeletal disorder in past 3 months? Y/N 395 (93%)
If Yes, mean number of visits in past 3 months to GP 1.6 (SD 1.3)
Episode duration (months) *median (n = 370) 7 (IQR 3–24)
Outcome expectation of physiotherapy (0 low -10 high) (n = 418) 7.5 (SD 1.8)
Pain catastrophising (0 low—10 high) (n = 422) 3.8 (SD 3.0)
General health rating (0 low—100 high) (n = 424) 75.3 (SD 19.9)
Number completing MSK-PROM (proxy for attending clinic)
Visit 1 (baseline) 417 (98.0%)
Visit 2 339 (79.8%)
Visit 3 270 (63.5%)
Visit 4 177 (41.6%)
Visit 5 101 (23.8%)
Visit 6 65 (15.3%)
Returned 3 month MSK-PROM follow-up 225 (52.9%)
Any MSK-PROM follow-up visit and/or three-month follow-up 364 (85.6%)
doi:10.1371/journal.pone.0124557.t002
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MSK-PROM items at the second visit with incidental missing data was: independence = 13, se-
verity of worst problem = 15, work = 12, activities = 13, Understanding = 11, Bothered = 12.
The sensitivity analysis using complete data for test re-test showed similar results with an ICC
of 0.98 (95% CI .96–.98).
Convergent construct validity. The Pearson correlation of the MSK-PROM and EQ-5D-
5L was 0.671 and boxplot illustrating the distribution characteristics of both tool scores is pre-
sented in Fig 2. The results demonstrate strong convergent construct validity between the
MSK-PROM and the EQ-5D-5L.
Responsiveness (sensitivity to change). Data at three-month follow-up were available for
225/425 (54%) of participants. Non-responders at three-month follow-up were younger (10
year mean difference) and had slightly lower MSK-PROM scores at baseline (1.4 mean lower)
compared to responders, but were similar in other baseline characteristics. Among responders,
the mean (SD) MSK-PROM score was 15.41 (4.93), and the mean (SD) change from baseline
was 3.97 (4.84), with 74.5% reporting better, 5.9% the same and 19.6% worse scores. The re-
sponsiveness statistics of the MSK-PROM are presented in Table 3. The MSK-PROM standard
error of measurement was 0.86.
Objective 4: MSK-PROM clinical feasibility and acceptability
The structured feedback workshop involved four patients, six physiotherapists, one manager
and two researchers. Patients felt the MSK-PROM together with the EQ-5D-5L successfully
captured relevant domains and was acceptable and feasible for use in clinical practice. The dis-
cussion of the potential mis-uses of the measure highlighted: the MSK-PROM is not considered
appropriate for asymptomatic conditions or in the context of preventative treatment, prior to
Fig 1. The distribution of mean scores at first visit for the MSK-PROM, EQ-5D-5L sum score and utility
score, and a combinedMSK-PROM and EQ-5D-5L score.
doi:10.1371/journal.pone.0124557.g001
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the development of symptoms. In one case, the patient described how the tool helped to de-
construct and explain the impact of her symptoms to her physiotherapist over the course of
treatment. Strong endorsement was provided by the other patient representatives. Clinicians
also felt the MSK-PROM was feasible and added value to the consultation by monitoring
changes over time. Some further minor improvements to the tool’s readability and comprehen-
sion were suggested and at the end of the workshop participants were unanimously in favour
of recommending the use of the MSK-PROM as fit for purpose to clinical colleagues or
fellow patients.
Fig 2. Boxplot presenting the distribution of MSK-PROM and EQ-5D-5L baseline sum scores.
doi:10.1371/journal.pone.0124557.g002
Table 3. Responsiveness of the MSK-PROM compared to the EQ-5D-5L.
MSK-PROM EQ-5D-5L Utility score EQ-5D-5L Raw sum score Combined MSK-PROM & EQ5D-
5L score
Baseline (n = 415) Mean (SD) 19.35 (4.28) 0.56 (0.23) 11.05 (3.34) 29.9 (6.64)
Three-month follow up (n = 225 FU)
Mean (SD)
15.41 (4.93) 0.67 (0.22) 9.450 (3.55) 23.87 (7.36)
Baseline to three-month change—
Mean (SD)
3.97 (4.84) -0.09 (0.22) 1.41 (3.21) 6.20 (7.13)
AUC (95% CI) 0.81 (0.72, 0.90) 0.71 (0.63, 0.79) 0.74 (0.64, 0.85) 0.81 (0.72, 0.90)
Effect size 0.93 0.39 0.42 0.93
Standardised response mean 0.82 0.41 0.44 0.87
doi:10.1371/journal.pone.0124557.t003
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Discussion
We have developed a brief patient reported outcome measure (PROM) to monitor health sta-
tus across a range of musculoskeletal pain disorders and validated key psychometric properties
with patients accessing physiotherapy. The new MSK-PROM has six items (including indepen-
dence, severity of the one thing that is most difficult, work interference, understanding how to
deal with the symptoms, ability to do activities/roles that matter, and overall impact) and is de-
signed so that it can be used alongside the EQ-5D-5L in routine clinical practice to assess prior-
ity outcome domains.
Having appropriate clinical tools to capture the impact from fluctuating musculoskeletal
symptoms is vital to help patients to better manage and monitor their own health[5]. Until
now a brief and feasible multi-dimensional clinical tool capturing the key outcomes which mat-
ter to individuals with musculoskeletal pain and musculoskeletal clinicians and services has
not been available. This is the first instrument specifically developed to address the need for
musculoskeletal services to report their healthcare outcomes using a combination of generic
and condition specific PROMs.
Having identified that the widely used EQ-5D-5L already captures a number of the priority
health outcomes for musculoskeletal patients, a particular strength of our approach has been to
reduce patient and clinician burden by designing the MSK-PROM to complement this existing
tool. The study results demonstrated that the MSK-PROM responsiveness (i.e. within group ef-
fect size and standardised response mean) is twice as large as the EQ-5D-5L, despite being sim-
ilarly brief and including the same Likert response scale. In addition, patients and clinician
feedback confirmed the MSK-PROM’s brevity and partnership with the EQ-5D-5L was partic-
ularly valued. In this study there was a deliberate decision to determine the optimal single item
to capture each construct identified in the consensus process, using the views of patients and
clinicians (face validity) rather than statistical testing. This approach was considered to be
more consistent with the study objective of developing a brief patient/user determined scale for
use in clinical practice rather than a new research measure. Further research is now needed to
compare the MSK-PROM responsiveness in other settings and with other condition specific
outcome measures. In addition, it is possible that whilst this instrument seeks to be a bespoke
measure for patients with musculoskeletal conditions, many of the domains identified seem
highly relevant for patients with other long-term conditions and future research could explore
the use of this tool with other patient groups.
The strengths of this study include strong patient and clinician involvement, the large vali-
dation cohort embedded within routine physiotherapy practice, and positive endorsement
both locally and nationally through an online survey with clinicians and patients. Limitations
include a substantial loss to follow-up in the cohort study and the differences in age identified
between responders and non-responders. The relatively low three-month follow-up rate of
54% was anticipated as our method of follow-up was fully embedded within routine practice in
order to provide a realistic estimate for future physiotherapy clinical audits using the
MSK-PROM.
Further research is now required to explore the ability of the MSK-PROM to describe vari-
ability in outcomes of healthcare across different services and explore its potential for bench-
marking musculoskeletal physiotherapy service performance using appropriate statistical
adjustment for clinical case-mix. Generic methods to case-mix adjust PROMs data have been
published[30] but specific methodology for case-mix adjustment in musculoskeletal popula-
tions is still in relative infancy with further research required[21]. In the Netherlands and the
UK, PROMs data are being mandated by purchasers of musculoskeletal healthcare in combina-
tion with patient experience measures for accountability purposes[31] and therefore in the
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future more data are likely to become available. For example, the Royal Dutch Society for Phys-
ical Therapy has commissioned a national four-year programme with a series of pilot projects
to stimulate the use of PROMs in physiotherapy practice and begin collecting a central source
of musculoskeletal service performance information. This trend may soon be followed in the
UK, although the integrated use of PROMs on a wide scale will need to overcome identified
barriers including establishing a culture of routine data collection, and overcoming fears about
how PROMs data may be used by different stakeholders with conflicting interests[32,33].
Having confirmed the MSK-PROM is reliable, responsive and is acceptable and feasible for
use in routine practice, we believe it is ready for use in routine musculoskeletal physiotherapy
practice. The Keele MSK-PROM tool is freely available for use from the following website
http://www.keele.ac.uk/pchs/disseminatingourresearch/researchtools/keelemsk-promtool/ and
is recommended for use alongside the EQ-5D-5L in order to capture the key outcome domains
for patients with musculoskeletal pain conditions.
Supporting Information
S1 Text. Musculoskeletal Case-mix Descriptors.
(PDF)
S2 Text. Survey Feedback Comments.
(PDF)
S3 Text. The Keele MSK-PROM Tool.
(PDF)
Acknowledgments
This abstract presents independent research funded by the National Institute for Health Re-
search (NIHR) under its Programme Grants for Applied Research Programme (Grant Refer-
ence Number PB-PG-0909-20283). http://www.nihr.ac.uk/funding/research-for-patient-
benefit.htm. Nadine Foster is supported through an NIHR Research Professorship (NIHR-RP-
011-015). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript. The views expressed are those of the authors and
not necessarily those of the NHS, the NIHR or the Department of Health.
We thank the physiotherapy teams that participated in the study and particularly the clini-
cians who agreed to take on the role of research facilitators in the physiotherapy services. We
thank patients for participating in the study. We thank two research user group members, Val-
erie Longmore and Bernard Colclough who were part of the study steering committee and Gail
Sowden, Consultant Physiotherapist who was involved in the early development of this project.
Ethical approval for the study’s development and validation phases were obtained separately
from the UK National Health Service Health Research Authority National Research Ethics Ser-
vice Committee for Yorkshire and the Humber-Leeds West (approval reference:11/EM/0095,
and approval reference:12/YH/0232). All participants provided informed written consent and
were remunerated according to INVOLVE recommendations(12).
Author Contributions
Conceived and designed the experiments: JH ET SH NF DW. Performed the experiments: JH
ET SH NF DW. Analyzed the data: JH ET. Contributed reagents/materials/analysis tools: JH
SH. Wrote the paper: JH ET SH NF DW.
Development and Validation of the MSK-PROM
PLOSONE | DOI:10.1371/journal.pone.0124557 April 30, 2015 12 / 14
References
1. FDA. Guidance for Industry: Patient-Reported OutcomeMeasures: Use in Medical Product Develop-
ment to Support Labelling Claims. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM375588.pdf
2. Devlin N, Appleby J. Getting the most out of PROMs: Putting health outcomes at the heart of NHS deci-
sion making. London: King's Fund and Office of Health Economics. 2010. Available: http://www.
kingsfund.org.uk/sites/files/kf/Getting-the-most-out-of-PROMs-Nancy-Devlin-John-Appleby-Kings-
Fund-March-2010.pdf
3. Haywood KL. 'Patient Reported Outcomes in the Rheumatic Diseases', Chapter 4 in Rheumatology:
Evidence-based Practice for Physiotherapists and Occupational Therapists, Editors: Dziedzic K, Ham-
mond A, London: Elsevier. 2010.
4. Imison C, Naylor C, Goodwin N, Buck D, Curry N, Addicott R, et al. Transforming our health care sys-
tem: Ten priorities for commissioners. The Kings Fund. 2011. Available: http://www.kingsfund.org.uk/
publications/articles/transforming-our-health-care-system-ten-priorities-commissioners
5. Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why?
Qual Life Res. 2009;Feb; 18(1): 115–23 doi: 10.1007/s11136-008-9430-6 PMID: 19105048
6. Darzi A. High Quality Care For All: NHS next stage review final report. Cm 7432. London: the Statio-
nery Office. 2008. Available: https://www.gov.uk/government/uploads/system/uploads/attachment_
data/file/228836/7432.pdf
7. Brooks R. EuroQol: the current state of play. Health Policy. 1996; 37: 53–72. PMID: 10158943
8. HerdmanM, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary test-
ing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10): 1727–36. doi: 10.
1007/s11136-011-9903-x PMID: 21479777
9. Janssen MF, Pickard AS, Golicki D, Gudex C, NiewadaM, Scalone L, et al. Measurement properties of
the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life
Res. 2013;Sep; 22(7): 1717–27. doi: 10.1007/s11136-012-0322-4 PMID: 23184421
10. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and
sensitive measure of disability in low-back pain. Spine. 1983; 8(2): 141–144. PMID: 6222486
11. Dawson J, Fitzpatrick R, Murray D, Carr A. Questionnaire on the perceptions of patients about total
knee replacement. Journal of Bone and Joint Surgery. 1998; 80: 63–69. PMID: 9460955
12. Kamaleri Y, Natvig B, Ihlebaek CM, Bruusgaard D. Localized or widespread musculoskeletal pain:
does it matter? Pain. 2008;Aug15; 138(1): 41–6. PMID: 18077092
13. Hartvigsen J, Natvig B, Ferreira M. Is it all about a pain in the back? Best Pract Res Clin Rheumatol.
2013;Oct; 27(5): 613–23. doi: 10.1016/j.berh.2013.09.008 PMID: 24315143
14. Hanley B, Bradburn J, Barnes M, Evans C, Goodare H, Kelson M, et al. Involving the public in NHS,
public health, and social care research: Briefing notes for researchers. ( second edition) INVOLVE.
2004.
15. Delbecq AL, VandeVen AH. "A Group Process Model for Problem Identification and Program Plan-
ning", Journal of Applied Behavioural Science. 1971; VII: 466–91.
16. Hill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE, et al. A primary care back pain screening
tool: identifying patient subgroups for initial treatment. Arthritis Rheum. 2008;15, 59(5): 632–41. doi: 10.
1002/art.23563 PMID: 18438893
17. Ware JE Jr. SF-36 Health Survey Update. Spine. 2000; 25: 3130–9. PMID: 11124729
18. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, et al. Protocol of the COSMIN
study: COnsensus‐based Standards for the selection of health measurement INstruments. BMCMed
Res Methodol. 2006; 6: 2. PMID: 16433905
19. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI
initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical
trials revisited. Osteoarthritis Cartilage. 2004; 12(5): 389–399. PMID: 15094138
20. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. IMMPACT. Core out-
come measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005; 113(1–2): 9–
19.
21. Resnik L, Liu D, Hart DL, Mor V. Benchmarking physical therapy clinic performance: statistical methods
to enhance internal validity when using observational data. Phys Ther. 2008; 88: 1078–1087. doi: 10.
2522/ptj.20070327 PMID: 18689608
22. Shao J, Zhong B. Last observation carry-forward and last observation analysis. Stat Med. 2003; 15;22:
2429–41. PMID: 12872300
Development and Validation of the MSK-PROM
PLOSONE | DOI:10.1371/journal.pone.0124557 April 30, 2015 13 / 14
23. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care.
1989; 27: S178–89. PMID: 2646488
24. Liang MJ, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopaedic evalu-
ation. Med Care. 1990; 28: 632–42. PMID: 2366602
25. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and
minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology. 2008:
61: 102–109. doi: 10.1016/j.jclinepi.2007.03.012 PMID: 18177782
26. Donner A, Eliasziw M. Sample size requirements for reliability studies. Statistics in Medicine. 1987;Jun;
6(4): 441–448. PMID: 3629046
27. Dunn KM, Croft PR. Classification of low back pain in primary care: using "bothersomeness" to identify
the most severe cases. Spine. 2005;15; 30(16): 1887–92. PMID: 16103861
28. Harmon C, Lambert MJ, Smart DW, Hawkins EJ, Nielsen SL, Slade K, et al. Enhancing outcome for po-
tential treatment failures: Therapist/client feedback and clinical support tools. Psychotherapy Research.
2007; 17(4): 379–392.
29. Newnham EA, Page AC. Bridging the gap between best evidence and best practice in mental health.
Clinical Psychology Review. 2009; 10: 1016.
30. Health and Social Care Information Centre. Hospital episode statistics: Provisional monthly Patient Re-
ported OutcomeMeasures (PROMs) in England—A guide to PROMsmethodology. 2013. Available:
http://www.hscic.gov.uk/media/1537/A-Guide-to-PROMs-Methodology/pdf/PROMS_Guide_v5.pdf
31. Van der Wees PJ, Nijhuis-van der Sanden MWG, Ayanian JZ, Black N, Westert GP, Schneider EC. In-
tegrating the use of patient-reported outcomes for both clinical practice and for performance measure-
ment: experts’ views from three countries. Submitted for publication.
32. Duncan EA, Murray J. The barriers and facilitators to routine outcomemeasurement by allied health
professionals in practice: a systematic review. BMC Health Serv Res. 2012; 12: 96. doi: 10.1186/1472-
6963-12-96 PMID: 22506982
33. Boyce MB, Browne JP, Greenhalgh J. The experiences of professionals with using information from pa-
tient-reported outcomemeasures to improve the quality of healthcare: a systematic review of qualitative
research. BMJ Qual Saf. 2014;Feb: 6.
Development and Validation of the MSK-PROM
PLOSONE | DOI:10.1371/journal.pone.0124557 April 30, 2015 14 / 14
